Crawford & Company (ESPR) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Sequential Quarter-Over-Quarter Growth in Total Retail Prescription Equivalents | 11.30 percent | FY2025-Q4 |
| Year-Over-Year Growth in Retail Prescription Equivalents | 34.00 percent | FY2025-Q4 |
| Commercial Lives Coverage for Nexlizet and Nexletol | 90.00 percent | FY2025-Q4 |
| Medicare Beneficiaries Coverage for Nexlizet and Nexletol | 90.00 percent | FY2025-Q4 |
| Healthcare Practitioners Writing Prescriptions | 30K | FY2025-Q3 |
| New-to-Brand Prescriptions Growth (Compared to Prior Quarter) | 8.00 percent | FY2024-Q4 |
Back to ESPR overview · ESPR earnings · ESPR holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.